Abstracts Archive - Page 2371 of 2425 - ACR Meeting Abstracts

Abstract Number: 762 • 2012 ACR/ARHP Annual Meeting
Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis
Yukiko Kimura¹, Jennifer E. Weiss², Kathryn L. Haroldson¹, Tzielan C. Lee³, Marilynn G. Punaro⁴, Sheila K. Feitosa de Oliveira⁵, C. Egla Rabinovich⁶, Meredith P. Riebschleger⁷, Jordi Anton⁸, Peter R. Blier⁹, Valeria Gerloni¹⁰, Melissa M. Hazen¹¹, Elizabeth Kessler¹², Karen Onel¹³, Murray H. Passo¹⁴, Robert M. Rennebohm¹⁵, Carol A. Wallace¹⁶, Patricia Woo¹⁷, Nico M. Wulffraat¹⁸ and CARRAnet Investigators¹⁹, ¹Pediatric Rheumatology, JM Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ³Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ⁵Pediatric Rheumatology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ⁷Pediatric Rheumatology & Health Services Research, University of Michigan, Ann Arbor, MI, ⁸Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, ⁹Pediatrics, Baystate Children's Hospital, Springfield, MA, ¹⁰Pediatric Rheumatology, Gaetano Pini Chair of Rheum, Milan, Italy, ¹¹Division of Immunology, Boston Children's Hospital, Boston, MA, ¹²Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ¹³Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ¹⁴Pediatrics, Medical University of South Carolina, Charleston, SC, ¹⁵Pediatric Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ¹⁶Pediatrics, Seattle Childrens Hospital, Seattle, WA, ¹⁷Division of Infection and Immunity, University College London, London, United Kingdom, ¹⁸Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁹Durham
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is characterized by fevers, rash and arthritis, for which IL1 and IL6 inhibitors appear to be effective. Pulmonary artery…
Abstract Number: 763 • 2012 ACR/ARHP Annual Meeting
Incidence of Selected Opportunistic Infections Among Children with Juvenile Idiopathic Arthritis
Timothy Beukelman¹, Fenglong Xie², John Baddley³, Lang Chen⁴, Elizabeth S. Delzell⁵, Carlos Grijalva⁶, Melissa L. Mannion¹, Nivedita M. Patkar⁷, Kenneth G. Saag⁸, Kevin L. Winthrop⁹ and Jeffrey R. Curtis², ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Preventive Medicine, Vanderbilt University, Nashville, TN, ⁷Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Div Clinical Immun & Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: There may be an increased risk of opportunistic infections among children with juvenile idiopathic arthritis (JIA), especially with exposure to immunosuppressant medications. No controlled…
Abstract Number: 764 • 2012 ACR/ARHP Annual Meeting
The Impact of Adalimumab On Growth in Patients with Juvenile Idiopathic Arthritis
D. J. Lovell¹, Nicolino Ruperto², Katerina Jarosova³, Dana Nemcova⁴, Veronika Vargova³, Hartmut Michels³, Elizabeth Chalom⁵, Norman Ilowite⁵, Carine Wouters⁶, Hermine Brunner⁷, Karolyn Kracht⁸, Hartmut Kupper⁹, Edward Giannini⁵, Alberto Martini¹⁰ and Neelufar Mozaffarian¹¹, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genova, Italy, ³PRINTO, Gaslini Institute, Genova, Italy, ⁴Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ⁵PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁶PRINTO, Genoa, Italy, ⁷PRCSG, Cincinnati Children’s Hospital Medical Center, Genova, Italy, ⁸Abbott, Abbott, Abbott Park, IL, ⁹Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ¹⁰Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ¹¹Abbott, Abbott Park, IL
Background/Purpose: Children with juvenile idiopathic arthritis (JIA) often exhibit growth impairments. Treatment with adalimumab (ADA) has been shown to be safe and effective in JIA…
Abstract Number: 765 • 2012 ACR/ARHP Annual Meeting
A Prediction Rule for the Development of Rheumatoid Arthritis: A Prospective Cohort Study of Seropositive Arthralgia Patients
Lotte van de Stadt¹, B. I. Witte², W.H. Bos¹ and Dirkjan van Schaardenburg¹, ¹Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Patients presenting with arthralgia and a positive test for anti-cyclic citrullinated peptide antibodies (aCCP) and/or IgM rheumatoid factor (IgM-RF) (seropositive) are at risk for…
Abstract Number: 766 • 2012 ACR/ARHP Annual Meeting
Anemia May Provide Clinically Relevant Information Beyond Conventional Disease Activity Assessment to Predict Radiographic Damage Progression in Rheumatoid Arthritis
Burkhard Moller¹, Frauke Förger², Peter M. Villiger³ and Axel Finckh⁴, ¹Rheumatology, Inselspital University Hospital, Bern, Switzerland, ²Rheumatology, Clinical Immunology and Allergology, Inselspital University Hospital of Bern, Bern, Switzerland, ³Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, ⁴Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland
Anemia may provide clinically relevant information beyond conventional disease activity assessment to predict radiographic damage progression in Rheumatoid ArthritisBurkhard Möller, Frauke Förger, Peter M. Villiger,…
Abstract Number: 767 • 2012 ACR/ARHP Annual Meeting
Patients with Early Inflammatory Arthritis Who Fulfil the 2010 American College Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis Have Increased Mortality Compared to Those Who Do Not: Results From the Norfolk Arthritis Register
Jh Humphreys¹, Suzanne Verstappen², Mark Lunt³, Jackie Chipping⁴, Kimme Hyrich⁵, Tarnya Marshall⁶ and Deborah Symmons⁷, ¹Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit,, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit,, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁴Norfolk Arthritis Register, School of Medicine Health Policy and Practice Faculty of Health UEA, Norwich, United Kingdom, ⁵Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁶Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁷Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose: Mortality is increased in rheumatoid arthritis (RA) in comparison with the general population. The majority of studies have used the 1987 ACR criteria to…
Abstract Number: 768 • 2012 ACR/ARHP Annual Meeting
An Easy to Use Referral Model for Arthritis From the Rotterdam Early Arthitis Cohort
C. Alves¹, Jolanda J. Luime¹, Darian P. Shackleton², P.J. Barendregt³, A.H. Gerards⁴ and Johanna M.W. Hazes¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Medisch Centrum Parklaan, Netherlands, ³Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands
Background/Purpose: The first hurdle general practitioners (GPs) face to identify Rheumatoid Arthritis(RA) is to recognize presence of arthritis. Due to the low incidence of arthritis…
Abstract Number: 769 • 2012 ACR/ARHP Annual Meeting
2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria Predicts Radiogical, but Not Clinical Outcomes At 18 Months Into Disease in a Canadian Early Arthritis Cohort
Ariel Masetto¹, Arthur J. Fernandes², Patrick Liang³, Pierre Cossette⁴ and Gilles Boire⁵, ¹Rheumatology, CHUS, Fleurimont, QC, Canada, ²Rheumatology Division, Universite de Sherbrooke, Sherbrooke N, Canada, ³Rheumatology Division, CHUS, Sherbrooke, QC, Canada, ⁴Internal Medicine Departement, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: The potential of the 2010 ACR/EULAR rheumatoid arthritis (RA) classification criteria to discriminate early arthritis patients according to their clinical and radiological outcomes needs…
Abstract Number: 770 • 2012 ACR/ARHP Annual Meeting
Is Late Onset Rheumatoid Arthritis (LORA) Really a Distinct Entity of RA? Results From the Swiss Observational Cohort
Ruediger Mueller¹, Toni Kaegi¹, Axel Finckh² and Johannes von Kempis¹, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is generally described as a disease with two peaks of onset, either late (late onset RA, LORA) or early (young onset…
Abstract Number: 771 • 2012 ACR/ARHP Annual Meeting
Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): 1-Year Results
Yoshiya Tanaka¹, Shintaro Hirata¹, Shunsuke Fukuyo¹, Masao Nawata², Satoshi Kubo², Kunihiro Yamaoka² and Kazuyoshi Saito¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Discontinuing anti-TNF therapy after achieving a stable low disease activity (LDA) or remission (REM) state in rheumatoid arthritis (RA) has become an important area…
Abstract Number: 772 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared with Adalimumab Monotherapy in Patients with Rheumatoid Arthritis: Results of a 24-Week Study
Arthur Kavanaugh¹, Paul Emery², Ronald F. van Vollenhoven³, Ara H. Dikranian⁴, Rieke Alten⁵, Micki Klearman⁶, David Musselman⁷, Sunil Agarwal⁷, Jennifer Green⁸ and Cem Gabay⁹, ¹UCSD School of Medicine, La Jolla, CA, ²Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ³Karolinska Institute, Stockholm, Sweden, ⁴San Diego Arthritis Medical Clinic, San Diego, CA, ⁵Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁶Roche, South San Francisco, CA, ⁷Genentech Inc, South San Francisco, CA, ⁸Roche, Welwyn Garden City, United Kingdom, ⁹Rheumatology, Geneva University Hospitals, Geneva, Switzerland
Background/Purpose: Approximately one-third of RA pts treated with biologics receive them as monotherapy (ie, without other DMARDs).1-3 Although tocilizumab (TCZ), an IL-6 receptor inhibitor, has…
Abstract Number: 733 • 2012 ACR/ARHP Annual Meeting
Intra-Articular Injection of Adipose-Derived Stem Cells Inhibits Activation of the Synovium and Protects Against Cartilage Damage and Enthesophyte Formation in Murine Experimental Osteoarthritis
Peter L.E.M. van Lent¹, Menno C. ter Huurne², Arjen B. Blom³, Rik Schelbergen³, Louis Casteilla⁴, Thomas Vogl⁵, Johannes Roth⁵, Roxane Blattes⁴, Christian Jorgensen⁶ and Wim B. van den Berg⁷, ¹Rheumatology Research & Advanced Therpeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴STROMALab UPS/CNRS UMR5273, INSERM U1031, Toulouse, France, ⁵Institute of Immunology, University of Muenster, Munster, Germany, ⁶Department of therapy & Immuno-Rhumatology, Hospital Lapeyronie, Montpellier, France, ⁷Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: OA lesions are treated with mesenchymal stem cells aiming to enhance tissue repair by transformation to eg. chondrocytes. Recently it has been shown that…
Abstract Number: 734 • 2012 ACR/ARHP Annual Meeting
Chemokine (C-C Motif) Receptor 2 Signaling Mediates Persistent Pain in Experimental Osteoarthritis
Rachel E. Miller¹, Phuong Tran², Rosalina Das², Nayereh Ghoreishi-Haack², Richard J. Miller³ and Anne-Marie Malfait⁴, ¹Rheumatology/Biochemistry, Rush University Medical Center, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Molecular Biochemistry and Pharmacology, Northwestern University, Chicago, IL, ⁴Internal Medicine/Biochemistry, Rush University Medical Center, Chicago, IL
Background/Purpose: To investigate the role of MCP-1/CCR2 in the development of pain in osteoarthritis (OA) using a mouse model, destabilization of the medial meniscus (DMM).…
Abstract Number: 735 • 2012 ACR/ARHP Annual Meeting
Mass Spectrometry Assays of Plasma Biomarkers to Predict Radiographic Progression of Knee Osteoarthritis
Susan Y. Ritter¹, William M. Reichmann², Jamie E. Collins³, Alejandra Garces⁴, Bryan Krastins⁴, David Sarracino⁴, Mary Lopez⁴, Elena Losina³ and Antonios O. Aliprantis⁵, ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Orthopedics, Brigham and Women's Hospital, Boston, MA, ³Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ⁴Thermo Fisher Scientific BRIMS Center, Cambridge, MA, ⁵Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Biomarkers to identify osteoarthritis (OA) patients at risk for disease progression are needed. Recently, we performed a proteomic analysis of knee synovial fluid from…
Abstract Number: 736 • 2012 ACR/ARHP Annual Meeting
Inhibition of Interleukin-17 Signaling Via De-Ubiquitinatio
Sarah L. Gaffen¹ and Abhishek Garg², ¹Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology/Clinical Immun, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: IL-17A (IL-17) is a proinflammatory cytokine that contributes to the pathogenesis of various autoimmune diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and psoriasis.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].